| Hazard Information | Back Directory | [Uses]
CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research[1][2][3]. | [in vivo]
CTCE-0214 (intravenous injection; 1-25 mg/kg; once) treatment inhibits Lipopolysaccharide-induced plasma TNF-α production[1].
CTCE-0214 (intraperitoneal injection and intravenous injection; 25 mg/kg; once) decreases Zymosan-induced plasma TNF-α production[1]. | Animal Model: | Male CD-1 mice injected with Lipopolysaccharide[1] | | Dosage: | 1, 10, or 25 mg/kg | | Administration: | Intravenous injection; 1, 10, or 25 mg/kg; once | | Result: | Decreased LPS-induced plasma TNF-α production in a dose dependent manor with a 93% reduction.
Showed no significant effect on LPS-induced plasma IL-6 and IL-10 production.
|
| Animal Model: | Zymosan-induced peritonitis mice model[1] | | Dosage: | 25 mg/kg | | Administration: | Intraperitoneal injection and intravenous injection; 25 mg/kg; once | | Result: | Showed a significant reduction in plasma TNF-α (53 reduction, p<0.05).
|
| [IC 50]
SDF-1α-CXCR4 | [References]
[1] Fan H, et al. Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7. DOI:10.1007/s10753-011-9297-5
[2] Faber A, et al. The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J Biomed Biotechnol. 2007;2007(3):26065. DOI:10.1155/2007/26065
[3] Li K, et al. Small peptide analogue of SDF-1alpha supports survival of cord blood CD34+ cells in synergy with other cytokines and enhances their ex vivo expansion and engraftment into nonobese diabetic/severe combined immunodeficient mice. Stem Cells. 2006 Jan;24(1):55-64. DOI:10.1634/stemcells.2005-0082 |
|
| Company Name: |
YantaiBio
|
| Tel: |
13758194781 |
| Website: |
|
| Company Name: |
Fuan Bio
|
| Tel: |
15002819872 |
| Website: |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|